Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Dr. Francesco  Galimi M.D., Ph.D.

Chief Medical Officer & Senior Vice President

Dr. Aya  Jakobovits Ph.D.

Founder & Independent Director

Dr. Blake  Aftab Ph.D.

Senior Vice President & Chief Scientific Officer

Mr. Brian Nicholas Harvey

Chief Financial Officer

Dr. Donald  Healey Ph.D.

Chief Technology Officer

Ms. Amy  Locke

Chief Human Resource Officer

Dr. Nancy L. Boman M.D., Ph.D.

Senior Vice President & Chief Regulatory Officer

Biotehnoloģija

Adicet Bio, Inc.

Adicet Bio, Inc. Vadības struktūra

Informācija par vadību